tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Innovent Biologics: China’s NMPA approves NDA for Dovbleron

Innovent Biologics (IVBXF) announced that China’s National Medical Products Administration has approved a New Drug Application of Dovbleron, a next-generation ROS1 tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have been previously treated with ROS1 TKIs.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1